Nishiwaki Hirotaka, Yamada Tomonori, Tachi Keiichirou, Iwasaki Hiroyasu, Hori Yasuki, Umemura Shuuichirou, Yamakawa Yoshihiro, Kurimoto Takuya, Ban Tesshin, Fujiwara Kei, Hayashi Katsumi, Nemoto Akira, Shiroko Junko, Orito Etsurou
Dept. of Gastroenterology, Nagoya Daini Red Cross Hospital.
Gan To Kagaku Ryoho. 2009 Oct;36(10):1663-6.
Recently, the significant efficacy of S-1 monotherapy or S-1 plus CDDP combination therapy has been reported. Docetaxel also has been reported to have favorable efficacy in gastric cancer. In addition, docetaxel can be administered in outpatient clinics. We investigated the efficacy and safety of S-1 plus docetaxel combination therapy for 35 naive patients with advanced gastric cancer. Docetaxel was administered at a dose of 40 mg/m(2) on day 1, and oral S-1 was administered at the full dose of 80 mg/m(2) twice daily for two weeks followed by one week rest. MST was 300 days, and the response rate was 42. 9%. Although leucopenia was observed in 31%, all patients were able to be continue this therapy. In conclusion, we considered that this S-1 plus docetaxel combination therapy was effective and safe in advanced gastric cancer, and convenient for outpatients.
最近，有报道称S-1单药治疗或S-1联合顺铂治疗具有显著疗效。多西他赛在胃癌治疗中也被报道有良好疗效。此外，多西他赛可在门诊给药。我们研究了S-1联合多西他赛治疗35例初治晚期胃癌患者的疗效和安全性。多西他赛在第1天以40mg/m²的剂量给药，口服S-1以80mg/m²的全剂量每日两次给药，持续两周，随后休息一周。中位生存期为300天，有效率为42.9%。虽然31%的患者出现白细胞减少，但所有患者均能够继续该治疗。总之，我们认为这种S-1联合多西他赛治疗方案对晚期胃癌有效且安全，对门诊患者也很方便。
